Topical 5-aminolevulinic acid photodynamic therapy with novel approach successfully treated refractory deep male urethral condyloma acuminata: A retrospective case series.

To the Editor: Deep male urethral condyloma acuminata (MUCA) remains an intractable problem in clinical practice. Because of the deep anatomical location, topical drug therapy, surgical treatment, or holmium laser are all restricted, with high recurrence rates and potentially severe complications such as urethral stenosis and urethral perforation. Five-aminolevulinic acid photodynamic therapy (ALA-PDT) has demonstrated high efficacy, good safety, and low recurrence in MUCA in previous studies. 1 Wang X.L. Wang H.W. Wang H.S. Xu S.Z. Liao K.H. Hillemanns P. Topical 5-aminolaevulinic acid-photodynamic therapy for the treatment of urethral condylomata acuminata. Br J Dermatol. 2004; 151: 880-885https://doi.org/10.1111/j.1365-2133.2004.06189.x Google Scholar ,2 Photodynamic Therapy Research CenterChinese Society of DermatologyChinese Association of Rehabilitation DermatologyPhotomedicine Therapeutic Equipment GroupCommittee on Skin Disease and Cosmetic DermatologyChina Association of Medical EquipmentChinese guidelines for clinical application of aminolevulinic acid-based photodynamic therapy in dermatology (2021 edition). Chin J Dermatol. 2021; 54: 1-9https://doi.org/10.35541/cjd.20200731 Google Scholar However, improper delivery of photosensitizers or inaccurate illumination may affect the treatment outcome of ALA-PDT in deep MUCA.